



**World Health
Organization**

**Draft Agenda
Meeting of the Strategic Advisory Group of Experts on Immunization (SAGE)
27 - 29 October 2009
CCV/CICG, Geneva**

Tuesday, 27 October 2009

Time	Session	Purpose of session, target outcomes and questions for SAGE	
09:00	Welcome - introduction		20mn
09:20	Report from IVB Director including status of implementation of recommendations Presentation: J.-M. Okwo-Bele, WHO, 20mn Discussion: 20mn	FOR INFORMATION	40mn
10:00	Regional priorities, major policy and implementation issues: report from AMRO, EURO and WPRO Presentation: C. Ruiz-Matus, WHO, 20mn Discussion: 20mn	FOR INFORMATION & DISCUSSION	2hrs
10:40	Coffee/tea break	Break	30mn
11:10	Presentation: R. Martin, WHO, 20mn Discussion: 20mn Presentation: D. Sniadack, WHO, 20mn Discussion: 20mn		
12:30	Lunch	Break	1hr 30mn

14:00	<p>Feasibility of measles eradication Update on the progress to implement the work plan including a review of scenarios to be addressed in the economic analysis A. Dabbagh, WHO, 20mn Discussion: 40mn</p>	<p>FOR INFORMATION AND DISCUSSION In the context of the study to estimate the cost and cost-effectiveness of measles eradication, SAGE will be asked if the proposed target date for eradication (i.e., 2020) and the vaccination strategies being modelled before and after eradication reasonable?</p>	1hr
	<p>Report from the GAVI Alliance secretariat Presentation: N. Schwalbe, GAVI Alliance, 20mn Discussion: 20mn</p>	<p>FOR INFORMATION</p>	40mn
15:40	Coffee/tea break	Break	30mn
16:10	<p>Reports from other Advisory Committees in Immunization -Global Advisory Committee on Vaccine Safety (GACVS) report of June 2009 -Report of May 2009 Initiative for Vaccine Research Advisory Committee (IVAC) As reports will be available, P. Smith, Chair of GACVS, and M.-P. Kieny in absence of P. Ndumbe, Chair of IVAC will address questions and no formal presentations will be delivered -Report of September 2009 Technologies and Logistics Advisory Committee (TLAC) meeting, B. Weniger, Chair of TLAC, 10mn presentation -Report of October 2009 Quantitative Immunization and Vaccines Related Research Committee (QUIVER) meeting, A. Hinman, Chair QUIVER, 10mn presentation - Report of October 2009 Expert Committee on Biological Standardization (ECBS) meeting, P. Minor, Chair of ECBS, 10mn presentation Discussion: 30mn</p>	<p>FOR INFORMATION</p>	1hr
17:10	<p>Developing an evidence based approach to design immunization schedules--Progress report Project update, P. Fine, LSHTM, 20mn Discussion: 20mn</p>	<p>FOR INFORMATION</p>	40mn
18:00	Cocktail		

Wednesday, 28 October 2009

08:30	<p>Cholera vaccine Introduction, J. Abramson, SAGE Member and Chair ad-hoc Working Group, 10mn</p> <p>Global situation and disease burden for cholera, D. Sack, John Hopkins, 15mn</p> <p>Cholera vaccines, D. Steele, PATH, 15mn</p> <p>Cholera vaccine use: the public health perspective and proposed recommendations, D. Legros, WHO, 20mn</p> <p>Discussion: 1 hr</p>	<p>FOR DECISION Updated recommendations on use of cholera vaccine leading to necessary updating of current vaccine position paper.</p>	2hrs
10:30	Coffee/tea break	Break	30mn
11:00	<p>Malaria vaccine Overview of GSK/MVI RTS,S/AS01 malaria vaccine: vaccine composition; phase 1-2 clinical trial data; phase 3 design/status C. Loucq, PATH MVI, 15mn</p> <p>IVR/Global Malaria Programme Joint Technical Expert Group on malaria vaccines, V. Moorthy, IVR, 5mn</p> <p>Discussion: 20mn</p>	<p>FOR INFORMATION</p>	40mn
11:40	<p>Intermittent malaria treatment co-administered with immunization</p> <p>Orientation to and purpose of the session, T. Goodman, WHO, 5mn</p> <p>Overview of IPTi and WHO's Global Malaria Programme's Policy, P. Olumese, GMP, WHO, 15mn</p> <p>Impact of IPTi on the serological responses to vaccination D. Goldblatt, WHO Advisory Committee member, 15mn</p>	<p>FOR DECISION SAGE decision on whether to recommend IPTi co-administration with immunization services.</p>	2hrs
12:15	Lunch	Break	1hr 20mn
13:35	<p>Intermittent malaria treatment co-administered with immunization (contd.) IPTi Implementation Experiences in Africa, A. DeSousa, UNICEF and D. Schellenberg, LSHTM, 25mn</p> <p>Discussion: 1hr</p>	<p>FOR DECISION</p>	

15:00	Coffee/tea break	Break	30mn
15:30	<p>Pandemic influenza A (H1N1) vaccine Update on epidemiology and disease burden, S. Briand, WHO, 15mn</p> <p>Overview of pandemic modeling: projection of H1N1 epidemiology and impact of vaccination, S. Cauchemez, Imperial College, 15mn</p> <p>Update on vaccine availability, M.-P. Kieny, WHO, 15mn</p> <p>Update on vaccine immunogenicity: preliminary results from clinical trials, D. Wood, WHO, 15mn</p> <p>Update on safety: Results from clinical trials and post-marketing surveillance organized, D. Pfeifer, WHO, 15mn</p> <p>Update on programmatic issues, T. Cherian, WHO, 15mn</p> <p>Discussion: 1hr</p>	<p>FOR DISCUSSION AND DECISION SAGE will be asked to answer the following questions:</p> <p>What is the relevance and prominence of current SAGE's recommendations on use of H1N1 vaccine in the light of current epidemiology and availability of vaccine?</p> <p>What is the needed number of doses?</p> <p>Can seasonal and pandemic vaccines be co-administered?</p> <p>Is obesity as such a risk factor for complications of H1N1?</p> <p>Does the previous SAGE statement on type of vaccine for pregnant women still stand in the light of vaccine availability?</p> <p>What should the formulation of the seasonal vaccine for the Southern Hemisphere 2010 season be?</p>	2hrs 30mn
18:00	End of meeting		

Thursday, 29 October 2009

08:30	<p>Epidemiology of unvaccinated infants Outline of the methodology adopted to answer the SAGE question, K. Banerjee, WHO, 5mn</p> <p>Analysis of Demographic and Health surveys (DHS) and Multi Indicators Cluster Surveys (MICS) survey data, X. Bosch-Capblanch, Swiss Tropical Institute, 15mn</p> <p>Analysis of articles published in peer reviewed scientific journals, J. Rainey, US CDC, 15mn</p> <p>Analysis of articles published in the grey literature, R. Steinglass, Immunization Basics, 15mn</p> <p>Discussion to seek clarifications on the specific studies/analysis, 40mn</p>	<p>FOR DISCUSSION -Review reasons why children are not reached by vaccination</p> <p>-Discuss need for further analysis or studies and how to translate the results into concrete strategies for improving coverage</p>	2hrs 30mn
-------	---	--	-----------

10:00	Coffee/tea break	Break	30mn
10:30	<p>Epidemiology of unvaccinated infants (contd.) Main findings from the previous presentations, proposed next steps, D. Durrheim, SAGE member, 10mn</p> <p>Discussion on next steps and operationalization of the knowledge gained from the analysis, 50mn</p>		
11:30	<p>Polio eradication Findings of the Independent Evaluation of the Major Barriers to Interrupting Poliovirus Transmission, A. Jaffer, Oman, MOH, Evaluation Chair, 20mn</p> <p>Discussion: 30mn</p> <p>Outbreaks following importation in previously polio-free countries, N. Grassly, Imperial College, 15mn</p> <p>Discussion: 15mn</p>	<p>FOR DISCUSSION AND DECISION Update on progress in overcoming barriers to interrupting polio transmission achieving, focus on data analysis in security-affected areas and on the issue of international polio spread. For discussion.</p> <p>Report of the IPV working group which will propose recommendations on a polio vaccine Position Paper. For decision.</p>	2hrs 30mn
12:40	Lunch	Break	1hr
13:40	<p>Polio eradication (contd.) Polio Eradication Tools - Outcomes & Programmatic Implications of Recent Trials on bOPV, high-titre mOPV1 and IPV, R. Sutter WHO & S. Cochi, Chair ACPE, 10mn</p> <p>Discussion: 10mn</p> <p>WHO Position Paper on Routine Polio Immunization - Major Recommendations, L. Miller, Chair IPV WG, 20mn</p> <p>Discussion: 30mn</p>		
15:00	Coffee/tea break	Break	30mn

15:30	<p>Pertussis control Report form the pertussis Working Group, E. Miller, SAGE member and Chair of Pertussis Working Group Chair, 30mn</p> <p>Discussion: 1hr 30mn</p>	<p>FOR DISCUSSION AND DECISION</p> <p>Overall purpose: Review the impact of current pertussis vaccination strategy and surveillance efforts in support of current control efforts.</p> <p>Propose necessary adjustments of current control goals and surveillance strategies and efforts.</p> <p>Provide updated recommendations on vaccine use (with a view to update the 2005 vaccine position paper on pertussis) - and identify important information gaps.</p> <p>This session will be focused on</p> <ol style="list-style-type: none"> 1. updating SAGE on progress of the Working Group and 2. requesting a SAGE decision with respect to the three following questions/issues <ol style="list-style-type: none"> 1. Should control goals be established for pertussis at regional and global level? 2. Are current surveillance efforts sufficient, and if not, what additional efforts should be recommended? 3. What should be the recommendation for the primary immunization schedule? <p>SAGE will also be asked to briefly discuss the next steps and questions identified by the Working Group with a view to come to a full set of decisions and recommendations at the April 2010 meeting (additional questions are related to supplementary vaccination activities including use of booster doses and vaccine issues such as comparative evaluation of aP and wP vaccines).</p>	2hrs
17:30	Closing		30mn
18:00	End of meeting		